Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 4/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | CDK7 | P50613 | 5/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.34 |
| ▸ | PAK4 | O96013 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | CLK2 | P49760 | 3/20 | 0.34 |
| ▸ | PRKX | P51817 | 3/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.34 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | MELK | Q14680 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785622 | 0.84 | MEN1 (0.56) | MEN1KMT2AALDH1A1BLML3MBTL1 | |
| SCHEMBL801603 | 0.73 | AURKA (0.46) | MEN1KMT2AALDH1A1BLML3MBTL1 | |
| SCHEMBL13055172 | 0.71 | RET (0.40) | AURKAAURKBSRCRETGSK3A | |
| SCHEMBL13055093 | 0.71 | EGFR (0.41) | EGFRGRM4AURKAROCK2ROCK1 | |
| SCHEMBL13055101 | 0.68 | MEN1 (0.44) | MEN1KMT2AALDH1A1EGFRAURKA | |
| SCHEMBL13054694 | 0.67 | EGFR (0.34) | EGFRGRM4AURKAAURKBSRC | |
| SCHEMBL13055057 | 0.67 | FADS1 (0.32) | EGFRGRM4AURKAAURKBLCK | |
| SCHEMBL13055155 | 0.67 | ABCG2 (0.44) | MEN1KMT2AALDH1A1CDK7CLK2 | |
| SCHEMBL13081874 | 0.66 | EGFR (0.34) | ALDH1A1EGFRGRM4AURKAAURKB | |
| SCHEMBL13054863 | 0.66 | SYK (0.41) | ALDH1A1AURKAAURKBSRCPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | LCK, CDK2, MKNK2 | MEN1 1366/4885KMT2A 762/4885ALDH1A1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.